NASDAQ:QLGN Qualigen Therapeutics Q3 2025 Earnings Report $1.09 +0.05 (+4.81%) As of 09/18/2026 ProfileEarnings HistoryForecast Qualigen Therapeutics EPS ResultsActual EPS-$4.68Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AQualigen Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AQualigen Therapeutics Announcement DetailsQuarterQ3 2025Date11/14/2025TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Qualigen Therapeutics Earnings HeadlinesQualigen Therapeutics Signs Exclusive License Agreement with the University of Louisville, Plans to Develop AS1411 for the Treatment of COVID-19December 13, 2025 | cnn.comQualigen Therapeutics Rebrands to AIxCrypto HoldingsNovember 17, 2025 | msn.comTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of Saudi Arabia's largest oil field, with potential to last two million years. While the One Big Beautiful Bill Act eliminated federal credits for solar, wind, and EVs, this energy source was reclassified alongside oil and nuclear power and given eight years of tax credits. Google signed a 15-year contract, and Bill Gates committed $100 million. One company controls the entire supply chain behind this discovery.September 20 at 1:00 AM | Behind the Markets (Ad)Qualigen Therapeutics stockholders approve all proposals with majority voteNovember 17, 2025 | msn.comFaraday Future Becomes Majority Shareholder in Qualigen Therapeutics, Preparing for Corporate Rebranding and Strategic Transformation on November 20November 16, 2025 | quiverquant.comQQualigen Therapeutics Stockholders Approve All Proposals with Majority Vote; Company to Rebrand as AIxCrypto Holdings, Inc. (Nasdaq: AIXC) Following November 20 Nasdaq Ceremony and Announces Transition into AI × Web3 StrategyNovember 16, 2025 | globenewswire.comSee More Qualigen Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Qualigen Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Qualigen Therapeutics and other key companies, straight to your email. Email Address About Qualigen TherapeuticsQualigen Therapeutics (NASDAQ:QLGN) is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and rare diseases. The company’s research programs are centered on small-molecule and other targeted therapeutic approaches intended to address biological mechanisms associated with tumor growth and disease progression. Qualigen’s development pipeline has included QN-302, an investigational small-molecule therapy being studied for potential use in oncology, including pancreatic cancer. The company has also pursued additional preclinical and clinical programs aimed at treating cancers and rare diseases. These products remain investigational and require further clinical development and regulatory review before they can be commercialized. The company is based in the United States and has roots in the diagnostics industry through its predecessor and affiliated operations. Qualigen Therapeutics became the successor to Ritter Pharmaceuticals following a 2020 corporate transaction involving Qualigen, Inc. Its current business is primarily focused on advancing its therapeutic pipeline rather than providing established commercial medical products.View Qualigen Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles J.B. Hunt's Stock Plunges After Market Misprices Profit WarningLennar’s Earnings Miss May Be Sending a Bigger Warning About U.S. HousingThese 3 Stocks Sit at the Center of NVIDIA’s Cybersecurity PushGold Has Gone Sideways, But These 3 Stocks Haven’tLennar's Q3 Miss Hides a Stronger Operating Story Beneath the Housing SlumpAeluma’s Selloff Could Be Setting Up Its Next Big MoveBraze Beat Expectations—Now 2 SaaS Peers Are in Focus Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
